Skip to main content
Clinical Trials/NCT06984952
NCT06984952RecruitingNot Applicable

Effectiveness of Enhanced Recovery After Surgery (ERAS) on Postoperative Recovery After Minimally Invasive Gastrectomy: A Multi-center Open-labeled Randomized Controlled Study

Seoul National University Hospital10 sites in 1 country308 target enrollmentStarted: June 13, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
308
Locations
10
Primary Endpoint
Proportion of patients who fulfilled all of the predefined discharge criteria

Study Overview

Brief Summary

This prospective, randomized, open-label, multicenter study is designed to evaluate the impact of an enhanced recovery after surgery (ERAS) protocol on the rate of meeting discharge criteria in patients undergoing minimally-invasive gastrectomy for gastric cancer. We hypothesize that implementation of our ERAS protocol will significantly increase the proportion of patients who meet standardized discharge criteria following minimally-invasive gastrectomy.

Detailed Description

Adult patients undergoing elective minimally invasive gastrectomy were randomly allocated to receive either the ERAS protocol (n = 154) or the conventional protocol (n = 154). The conventional group received the current standard perioperative care at our institution, whereas the ERAS group received a newly developed ERAS protocol, which included preoperative carbohydrate loading, reduced perioperative fasting duration, and multimodal opioid-sparing analgesia. The primary outcome was the proportion of patients who met standardized discharge criteria at 9:00 AM on postoperative day 4. Secondary outcomes included the EQ-5D-5L index assessed at 24, 48, 72, and 96 hours postoperatively; pain intensity at rest and during coughing measured using an 11-point numeric rating scale at 2, 24, 48, and 72 hours postoperatively; gastrointestinal dysfunction assessed using the I-FEED score at 24, 48, and 72 hours postoperatively; the incidence of postoperative nausea and vomiting within 0-24, 24-48, and 48-72 hours after surgery; the incidence of major postoperative complications classified by the Clavien-Dindo grading system during hospitalization; and postoperative length of hospital stay.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adults aged ≥19 years scheduled to undergo elective laparoscopic or robotic gastrectomy for gastric cancer
  • •American Society of Anesthesiologists physical status classification I to III
  • •Ability to provide written informed consent, demonstrate understanding of the study protocol, and complete patient-reported outcome measures appropriately

Exclusion Criteria

  • •Requirement for resection of organs other than the stomach during surgery (except for cholecystectomy)
  • •History of upper abdominal surgery (except for cholecystectomy)
  • •Known hypersensitivity to fentanyl, ropivacaine, acetaminophen, or non-steroidal anti-inflammatory drugs
  • •Determined by the investigator or study personnel to be otherwise unsuitable for participation in the study

Arms & Interventions

ERAS group

Experimental

Perioperative care for minimally-invasive gastrectomy is managed according to ERAS protocol.

Intervention: ERAS protocol (Procedure)

Conventional group

No Intervention

Perioperative care for minimally-invasive gastrectomy is managed according to our current perioperative practice

Outcomes

Primary Outcomes

Proportion of patients who fulfilled all of the predefined discharge criteria

Time Frame: At 9:00 AM on postoperative day

Discharge criteria were defined as meeting all of the following conditions: * Tolerance of a soft blended diet (SBD) for at least 24 hours * Unaided ambulation of at least 600 meters * Adequate pain control, defined as a numeric rating scale (NRS) score of ≤ 3, achieved with oral non-opioid analgesics * Absence of abnormal physical examination findings or laboratory test results

Secondary Outcomes

  • Postoperative pain score(postoperative 2, 24, 48, and 72 hours)
  • Quality of recovery assessed using the EQ-5D-5L questionnaire(postoperative 24, 48, and 72 hours)
  • Postoperative gastrointestinal dysfunction(postoperative 24, 48, and 72 hours)
  • Postoperative nausea and vomiting(From the end of surgery to 24, 48, and 72 hours postoperatively)
  • Major postoperative complication(At 30 days postoperatively)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Hojin Lee, MD, PhD

Professor

Seoul National University Hospital

Study Sites (10)

Loading locations...

Similar Trials